Journal
JOURNAL OF CONTROLLED RELEASE
Volume 300, Issue -, Pages 13-21Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2019.01.035
Keywords
Polymer drug conjugates; Dendritic polyglycerol; Monomethyl auristatin E; Stimuli-responsive; Anticancer
Funding
- Helmholtz Virtual Institute on Multifunctional Biomaterials for Medicine
- German Science Foundation (DFG) [392192146]
- National Natural Science Foundation of China [51761135117]
Ask authors/readers for more resources
Stimuli-responsive polymer-drug conjugates (PDCs) provide promising approaches in anticancer treatment. Here, we report the synthesis and biological evaluation of PDCs made of the highly potent antimitotic agent monomethyl auristatin E conjugated to dendritic polyglycerol and dendritic polyglycerol sulfate via a reductively cleavable, self-immolative disulfide linker. Cell viability assays with the human cancer cell lines A549 (lung carcinoma) and HeLa (cervix carcinoma) revealed that the drug's cytotoxicity was reduced by conjugation to the polymers, with the sulfated conjugates being more effective than the non-sulfated ones. Kinetic studies using real-time cell analysis indicated a retarded drug release from the polymers, with a much later cytotoxic response after treatment with the non-sulfated conjugates due to less cellular uptake, as confirmed by flow cytometry and confocal laser scanning microscopy. In contrast, the non-cleavable dPGS-MMAE conjugate that was synthesized for comparison was not cytotoxic under the same conditions. Overall, reductively cleavable dPGS-SS-MMAE conjugates showed promising results in vitro and good tolerability in vivo. Further in vivo studies are planned.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available